When was Symvivo founded?

Symvivo was founded in 2013 and raised its 1st funding round 7 years after it was founded.

Where is Symvivo located?

Symvivo is headquartered in Burnaby, Canada.

How many employees does Symvivo have?

As of Mar 31, 2026, the latest employee count at Symvivo is 1.

Is Symvivo a funded company?

Symvivo is a funded company, having raised an undisclosed amount across 2 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Oct 20, 2020.

When was the latest funding round of Symvivo?

Symvivo's latest funding was a $***** Grant (prize money) round on Jul 19, 2021, with participation from 1 investor.

Where does Symvivo rank among its competitors?

Symvivo ranks 2174th amongst 3654 active competitors, of which 1274 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was C4 Therapeutics, which secured $25M in Jan, 2024.

Who are the top competitors of Symvivo?

Symvivo's top competitors include Jazz Pharmaceuticals, Alnylam and Spark Therapeutics. Among them, C4 Therapeutics secured the most recent funding round in January, 2024.

Symvivo - 2026 Company Profile, Team, Funding & Competitors

Symvivo is a funded company based in Burnaby (Canada), founded in 2013 by Mark Fox. It operates as a Provider of site-specific delivery of genes for the treatment of a wide range of diseases. Symvivo has raised an undisclosed amount in funding. The company has 3654 active competitors, including 1274 funded and 865 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Alnylam and Spark Therapeutics.

Company Details

Provider of site-specific delivery of genes for the treatment of a wide range of diseases. The company uses proprietary bacTRL platform technology to deliver plasmid DNA, both orally and through IV administration, that enables a patient’s own cells to produce biologics. The company is developing therapeutics in the area of oral vaccines, oncology, immunology, and biologics.

Website: www.symvivo.com/
Email ID: *****@symvivo.com

Key Metrics

Founded Year

2013

Location

Burnaby, Canada

Stage

Funding Raised

Latest Funding Round

Grant (prize money), Jul 19, 2021, $*****

Investors

Canadian Space Agency

Ranked

2174^th among 3654 active competitors

Employee Count

1 as on Mar 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3602 more

View Symvivo's full profile

Symvivo has raised funding over 2 rounds. Its first funding round was on Oct 20, 2020. Its latest funding round was a Grant (prize money) round on Jul 19, 2021 for $*****. 1 investor participated in its latest round. Symvivo has 1 institutional investor.

Here is the list of recent funding rounds of Symvivo:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 19, 2021	2077332	Grant (prize money)	4965004	3128906	4087601	3052395
Oct 20, 2020	7298756	Grant (prize money)	9039319	5488558	8388244	Canadian Space Agency

Access funding benchmarks and valuations. Sign up today!

View details of Symvivo's funding rounds and investors

The founders of Symvivo is Mark Fox.

Here are the details of Symvivo's key team members:

Mark Fox: CSO and Founder of Symvivo.

Symvivo's Board of Directors

Symvivo's board has 4 active members. Blaine Hobson, Jennifer Hamilton, H. David Graves and Herbert Alexander Graves are independent board members.

Here is the list of Symvivo's board of directors:

Name	Type	Representing	Status	Duration
Blaine Hobson	Independent board member	-	Current	9y 2m
sgmebzc	Independent board member	-	Current	5y 2m
cxmbupt	Independent board member	-	Current	5y 9m
jowag{k	Independent board member	-	Current	9y 8m

View details of Symvivo's Founder profiles and Board Members

Symvivo's employee count trend

Symvivo has 1 employees as of Mar 26. Here is Symvivo's employee count trend over the years:

Uncover Symvivo's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Symvivo include Jazz Pharmaceuticals, Alnylam and Spark Therapeutics. Here is the list of Top 10 competitors of Symvivo, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Prospect Venture Partners, Versant Ventures ... & 14 others	82/100
2nd	Alnylam 2002, Cambridge (United States), Public	Developer of RNA interference-based therapeutics for multiple disorders	$17M	Colt Ventures, BB Biotech & 13 others	79/100
3rd	Spark Therapeutics 2013, Philadelphia (United States), Acquired	Developer of gene therapy for rare diseases	$82.8M	Sofinnova Investments, Brookside Capital & 6 others	76/100
4th	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Bezos Expeditions, Omega Funds & 17 others	75/100
5th	Kite Pharma 2009, Los Angeles (United States), Acquired	Developer of cancer immunotherapy products using genetic engineering	$97.7M	Alta Partners, Amgen Business Development ... & 10 others	75/100
6th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	74/100
7th	Juno Therapeutics 2013, Seattle (United States), Acquired	Global biopharmaceutical company discovering, developing, and delivering innovative medicines	$317M	BB Biotech, Bezos Expeditions & 14 others	74/100
8th	Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired	Novartis company, developing molecular nuclear medicine theranostics	$56.1M	Tamburi Investment Partners, Vivo Capital ... & 4 others	73/100
9th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	72/100
10th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
2174th	Symvivo 2013, Burnaby (Canada), Funding Raised	Provider of site-specific delivery of genes for the treatment of a wide range of diseases	-	Canadian Space Agency	24/100